RNS Number:9581T
VASTox plc
29 March 2007


                                   VASTox plc
                          ("VASTox" or "the Company")


                             DIRECTOR SHAREHOLDING

                      Chief Executive Officer buys shares



Oxford, UK, 29 March 2007 - VASTox plc (AIM: VOX) has been informed that on 28
March 2007 Dr Steven Lee, the Chief Executive Officer of the Company, purchased
10,000 ordinary shares of 10 pence each in the Company ("Ordinary Share") at a
price of #1.29 per Ordinary Share.


Following this purchase, Dr Lee has a total beneficial and non-beneficial
holding of 158,148 Ordinary Shares, representing 0.3 per cent of the current
issued share capital of the Company.


                                    - ends -


For more information, please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer                 Tel: +44 (0)1235 443951

Darren Millington, Chief Financial Officer


Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray            Tel: +44 (0)207 638 9571


About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.


VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.


VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.


The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX


Further information about the company is available at www.vastox.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RDSGIGDXIDDGGRC
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vox Valor Capital Charts.
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vox Valor Capital Charts.